Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 17 of 17 publications.

Cherian SV, Li C, Roche B, Reyes SA, Karanth S, Lal AP, Aisenberg GM, Estrada-Y-Martin RM. Predictive factors for success of awake proning in hypoxemic respiratory failure secondary to COVID-19: a retrospective cohort study. Respir Med. 2021 May;181:106379. doi: 10.1016/j.rmed.2021.106379

Rebordosa C, Aguado J, Plana E, Thomas S, Frances A, Lei A, Garcia-Gil E, Nuevo J, Perez-Gutthann S, Castellsague J. Use of aclidinium did not increase the risk of death in a noninterventional cohort study in the Clinical Practice Research Datalink (CPRD), United Kingdom. Respir Med. 2019 Jun;152:37-43. doi: 10.1016/j.rmed.2019.04.018

Carsin AE, Fuertes E, Schaffner E, Jarvis D, Anto JM, Heinrich J, Bellisario V, Svanes C, Keidel D, Imboden M, Weyler J, Nowak D, Martinez-Moratalla J, Gullon JA, Sanchez Ramos JL, Caviezel S, Beckmeyer-Borowko A, Raherison C, Pin I, Demoly P, Cerveri I, Accordini S, Gislason T, Toren K, Forsberg B, Janson C, Jogi R, Emtner M, Gomez Real F, Raza W, Leynaert B, Pascual S, Guerra S, Dharmage SC, Probst-Hensch N, Garcia-Aymerich J. Restrictive spirometry pattern is associated with low physical activity levels. A population based international study. Respir Med. 2019 Jan;146:116-23. doi: 10.1016/j.rmed.2018.11.017

Oakes G, Soleas I, Woodward G, Ko D, Eberg M, Tu J, Khan A, Wang X, Gorzkiewicz V, Couris C, Medved W, Leeb K. Comparison of outcomes following coronary artery bypass graft surgery and percutaneous coronary intervention in Ontario as reported by the cardiac care network of Ontario and the Canadian Institute for Health Information. Poster presented at the Canadian Cardiovascular Congress 2017; October 21, 2017. Vancouver, British Columbia. [abstract] Can J Cardiol. 2017 Oct; 33(10 Suppl):S134-5. doi: 10.1016/j.cjca.2017.07.261

Tu JV, Khan AM, Ng K, Chu A. Recent temporal changes in atherosclerotic cardiovascular diseases in Ontario: clinical and health systems impact. Can J Cardiol. 2017 Mar;33(3):378-84. doi: 10.1016/j.cjca.2016.11.009

Pujol J, Fenoll R, Macia D, Martinez-Vilavella G, Alvarez-Pedrerol M, Rivas I, Forns J, Deus J, Blanco-Hinojo L, Querol X, Sunyer J. Airborne copper exposure in school environments associated with poorer motor performance and altered basal ganglia. Brain Behav. 2016 Apr 22;e00467. doi: 10.1002/brb3.467

Prazma CM, Gern JE, Weinstein SF, Prillaman BA, Stempel DA. The association between seasonal asthma exacerbations and viral respiratory infections in a pediatric population receiving inhaled corticosteroid therapy with or without long-acting beta-adrenoceptor agonist: a randomized study. Respir Med. 2015 Oct;109(10):1280-6. doi: 10.1016/j.rmed.2015.06.010

Rottenkolber M, Voogd E, van Dijk L, Primatesta P, Becker C, de Groot MC, Plana E, Alvarez Y, Durand J, Slattery J, Afonso A, Requena G, Huerta C, Alvarez A, de Abajo F, Tauscher M, Hasford J, Fischer R, Reynolds R, Schmiedl S. Seasonal changes in prescribing of long-acting beta-2-agonists-containing drugs. Respir Med. 2015 Jul;109(7):828-37. doi: 10.1016/j.rmed.2015.01.010

Rottenkolber M, Rottenkolber D, Fischer R, Ibáñez L, Fortuny J, Ballarin E, Sabaté M, Ferrer P, Thürmann P, Hasford J, Schmiedl S. Inhaled beta-2-agonists/muscarinic antagonists and acute myocardial infarction in COPD patients. Respir Med. 2014 Aug;108(8):1075-90.

Grieger KD, Sayes C, Hendron CO, Rothrock G, Mansfield C, Jayanty RKM, Ensor D. Finding the key to responsible nanomaterial development. Ehs Today: The Magazine For Environment, Health And Safety Leaders. 2013 Dec 6.

Guerra S, Halonen M, Sherrill DL, Venker C, Spangenberg A, Carsin AE, Tares L, Lavi I, Barreiro E, Martinez-Moratalla J, Urrutia I, Sunyer J, Anto JM, Martinez FD. The relation of circulating YKL-40 to levels and decline of lung function in adult life. Respir Med. 2013 Dec;107(12):1923-30. doi: 10.1016/j.rmed.2013.07.013

Meads DM, McKenna SP, Doward LC, Pokrzywinski R, Revicki D, Hunter C, Glendenning GA. Development and validation of the Asthma Life Impact Scale (ALIS). Respir Med. 2010;104(5):633-43.

Earnshaw SR, Wilson MR, Dalal AA, Chambers MG, Jhingran P, Stanford R, Mapel DW. Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD. Respir Med. 2009 Jan 1;103(1):12-21.

Koenig SM, Murray JJ, Wolfe J, Andersen L, Yancey S, Prillaman B, Stauffer J, Dorinsky P. Does measuring BHR add to guideline derived clinical measures in determining treatment for patients with persistent asthma? Respir Med. 2008 May;102(5):665-73. doi: 10.1016/j.rmed.2007.12.023

Poulos C, Bahl R, Whittington D, Bhan MK, Clemens JD, Acosta CJ. A cost-benefit analysis of typhoid fever immunization programmes in an Indian urban slum community. J Health Popul Nutr. 2004 Jan 1;22(3):311-21.

Bahl R, Sinha A, Poulos C, Whittington D, Sazawal S, Kumar R, Mahalanabis D, Acosta CJ, Clemens JD, Bhan MK. Costs of illness due to typhoid fever in an Indian urban slum community: implications for vaccination policy. J Health Popul Nutr. 2004 Jan 1;22(3):304-10.

Castellsague J, Garcia-Rodriguez LA, Perez-Gutthann S, Agostinis L, Cattaruzi C, Troncon MG. Characteristics of users of inhaled long-acting beta 2-agonists in a southern European population. Respir Med. 1999 Oct 1;93(10):709-14.